Peak Bio, Inc.
PKBO · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.13 | 0.03 | -0.00 | 0.00 |
| FCF Yield | 0.00% | 0.00% | -46.29% | -391.52% |
| EV / EBITDA | 0.00 | 0.00 | 3.79 | -7.65 |
| Quality | ||||
| ROIC | 0.00% | 0.00% | 11.12% | 13.51% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | -0.60 | 0.44 | 0.58 | 2.79 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -49.43% | -15.23% |
| Free Cash Flow Growth | 0.00% | 0.00% | -161.73% | 36.14% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.00 | 2.12 | -7.51 |
| Interest Coverage | 0.00 | 0.00 | -1.11 | -3.10 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |